Overview

• The Cell Reports Medicine study, published August 29, introduces AlloCAR70-NKT as an allogeneic, stem cell–derived invariant NKT cell therapy for renal cell carcinoma.
• AlloCAR70-NKT cells express a CD70-directed CAR and are designed to resist immune rejection while remaining active within the tumor setting.
• Preclinical tests in RCC cell lines, primary patient samples, and orthotopic and metastatic mouse xenografts showed robust anti-tumor activity.
• The cells killed cancer through both CAR-mediated targeting and native NKT receptors, including in CD70-low tumors, and they remodeled the immunosuppressive tumor microenvironment.
• The therapy depleted CD70-positive alloreactive host cells to enhance persistence and showed a favorable safety profile in models, with clinical evaluation still to come.